Heidelberg
Germany
German Cancer Research Center (DKFZ) - Division of Immune Diversity (D150)
APOBEC2, terminal repressor, cell identity, dual expressor T/B cell, immune deficiency
Epitranscriptomics, RNA editing, cancer, B cell lymphoma, disease progression, RLR pathway, targeted base editing therapeutics
Trypanosome Lytic Factors, Variant Surface Glycoprotein, Natural Antibodies, Immunoglobulin M, Apolipoprotein L-1, Innate Immunity